{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:12:48Z","timestamp":1785255168514,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T00:00:00Z","timestamp":1438732800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s00228-015-1914-z","type":"journal-article","created":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T01:16:31Z","timestamp":1438650991000},"page":"1165-1173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension"],"prefix":"10.1007","volume":"71","author":[{"given":"Anna","family":"Sandqvist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Henrohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Eger\u00f6d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Hedeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wernroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Bondesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn","family":"Schneede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Wikstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,5]]},"reference":[{"issue":"2","key":"1914_CR1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/01.CIR.0000102381.57477.50","volume":"109","author":"R Budhiraja","year":"2004","unstructured":"Budhiraja R, Tuder RM, Hassoun PM (2004) Endothelial dysfunction in pulmonary hypertension. Circulation 109(2):159\u2013165","journal-title":"Circulation"},{"issue":"20","key":"1914_CR2","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"N Gali\u00e8","year":"2009","unstructured":"Gali\u00e8 N, Hoeper MM, Humbert M, Torbicki A, Vachiery J-L, Barbera JA et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30(20):2493\u20132537","journal-title":"Eur Heart J"},{"issue":"16","key":"1914_CR3","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","volume":"119","author":"VV McLaughlin","year":"2009","unstructured":"McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR et al (2009) ACCF\/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 119(16):2250\u20132294","journal-title":"Circulation"},{"issue":"23","key":"1914_CR4","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","volume":"111","author":"O Sitbon","year":"2005","unstructured":"Sitbon O, Humbert M, Ja\u00efs X, Ioos V, Hamid AM, Provencher S et al (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111(23):3105\u20133111","journal-title":"Circulation"},{"issue":"2","key":"1914_CR5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","volume":"327","author":"S Rich","year":"1992","unstructured":"Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327(2):76\u201381","journal-title":"N Engl J Med"},{"issue":"5","key":"1914_CR6","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0735-1097(91)90556-O","volume":"18","author":"S Rich","year":"1991","unstructured":"Rich S, Kaufmann E (1991) High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. J Am Coll Cardiol 18(5):1323\u20131327","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1914_CR7","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1378\/chest.06-2674","volume":"131","author":"DB Badesch","year":"2007","unstructured":"Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV (2007) Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131(6):1917\u20131928","journal-title":"Chest"},{"issue":"12 Suppl S","key":"1914_CR8","doi-asserted-by":"crossref","first-page":"68S","DOI":"10.1016\/j.jacc.2004.02.031","volume":"43","author":"HA Ghofrani","year":"2004","unstructured":"Ghofrani HA, Pepke-Zaba J, Barbera JA, Channick R, Keogh AM, Gomez-Sanchez MA et al (2004) Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 43(12 Suppl S):68S\u201372S","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1914_CR9","first-page":"1488","volume":"44","author":"HA Ghofrani","year":"2004","unstructured":"Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karada\u015f B et al (2004) Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 44(7):1488\u20131496","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"1914_CR10","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/hrt.2009.169417","volume":"95","author":"Z-C Jing","year":"2009","unstructured":"Jing Z-C, Jiang X, Wu B-X, Xu X-Q, Wu Y, Ma C-R et al (2009) Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. Heart Br Card Soc 95(18):1531\u20131536","journal-title":"Heart Br Card Soc"},{"issue":"1","key":"1914_CR11","first-page":"198","volume":"32","author":"MR Wilkins","year":"2008","unstructured":"Wilkins MR, Wharton J, Grimminger F, Ghofrani HA (2008) Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J Off J Eur Soc Clin Respir Physiol 32(1):198\u2013209","journal-title":"Eur Respir J Off J Eur Soc Clin Respir Physiol"},{"issue":"6","key":"1914_CR12","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.neuint.2004.03.016","volume":"45","author":"JD Corbin","year":"2004","unstructured":"Corbin JD, Beasley A, Blount MA, Francis SH (2004) Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Neurochem Int 45(6):859\u2013863","journal-title":"Neurochem Int"},{"issue":"10","key":"1914_CR13","first-page":"435","volume":"7","author":"U Gresser","year":"2002","unstructured":"Gresser U, Gleiter CH (2002) Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil\u2014review of the literature. Eur J Med Res 7(10):435\u2013446","journal-title":"Eur J Med Res"},{"key":"1914_CR14","unstructured":"Henrohn D, Sandqvist A, Hedeland M, Eger\u00f6d H, Bondesson U, Wikstr\u00f6m G. Acute hemodynamic response in relation to plasma vardenafil levels in patients with pulmonary hypertension. Br J Clin Pharmacol [Internet]. 2012 Apr 20 [cited 2012 May 28]; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22515706"},{"key":"1914_CR15","doi-asserted-by":"crossref","unstructured":"Jing Z-C, Yu Z-X, Shen J-Y, Wu B-X, Xu K-F, Zhu X-Y, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med [Internet]. 2011 Mar 11 [cited 2011 Apr 12]; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21471085","DOI":"10.1164\/rccm.201101-0093OC"},{"issue":"4","key":"1914_CR16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/bjp.2008.141","volume":"154","author":"HA Toque","year":"2008","unstructured":"Toque HA, Teixeira CE, Priviero FBM, Morganti RP, Antunes E, De Nucci G (2008) Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. Br J Pharmacol 154(4):787\u2013796","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1914_CR17","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1124\/jpet.105.092544","volume":"316","author":"CE Teixeira","year":"2006","unstructured":"Teixeira CE, Priviero FBM, Webb RC (2006) Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther 316(2):654\u2013661","journal-title":"J Pharmacol Exp Ther"},{"key":"1914_CR18","doi-asserted-by":"crossref","first-page":"718279","DOI":"10.1100\/2012\/718279","volume":"2012","author":"E Karasu-Minareci","year":"2012","unstructured":"Karasu-Minareci E, Ozbudak IH, Ozbilim G, Sadan G (2012) Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension. Sci World J 2012:718279","journal-title":"Sci World J"},{"key":"1914_CR19","doi-asserted-by":"crossref","unstructured":"Sandqvist AM, Henrohn D, Schneede J, Hedeland M, Eger\u00f6d HC, Bondesson UG, et al. High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. Eur J Clin Pharmacol [Internet]. 2012 Jun 26 [cited 2012 Jul 2]; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22732766","DOI":"10.1007\/s00228-012-1323-5"},{"key":"1914_CR20","doi-asserted-by":"crossref","unstructured":"Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A et al (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34\u2013D41","DOI":"10.1016\/j.jacc.2013.10.029"},{"issue":"4","key":"1914_CR21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.rmed.2009.11.015","volume":"104","author":"AR Tonelli","year":"2010","unstructured":"Tonelli AR, Alnuaimat H, Mubarak K (2010) Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med 104(4):481\u2013496","journal-title":"Respir Med"},{"issue":"6","key":"1914_CR22","first-page":"1103","volume":"30","author":"T Thenappan","year":"2007","unstructured":"Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M (2007) A USA-based registry for pulmonary arterial hypertension: 1982\u20132006. Eur Respir J Off J Eur Soc Clin Respir Physiol 30(6):1103\u20131110","journal-title":"Eur Respir J Off J Eur Soc Clin Respir Physiol"},{"issue":"6","key":"1914_CR23","first-page":"1354","volume":"33","author":"Z-C Jing","year":"2009","unstructured":"Jing Z-C, Jiang X, Han Z-Y, Xu X-Q, Wang Y, Wu Y et al (2009) Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J Off J Eur Soc Clin Respir Physiol 33(6):1354\u20131360","journal-title":"Eur Respir J Off J Eur Soc Clin Respir Physiol"},{"issue":"4","key":"1914_CR24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.rmed.2009.11.010","volume":"104","author":"EC Oliveira","year":"2010","unstructured":"Oliveira EC, Ribeiro ALP, Amaral CFS (2010) Adenosine for vasoreactivity testing in pulmonary hypertension: a head-to-head comparison with inhaled nitric oxide. Respir Med 104(4):606\u2013611","journal-title":"Respir Med"},{"issue":"3","key":"1914_CR25","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijcard.2010.04.093","volume":"147","author":"D Zhang","year":"2011","unstructured":"Zhang D, Zhu X, Meng J, Xue H, Sheng X, Han X et al (2011) Acute hemodynamic responses to adenosine and iloprost in patients with congenital heart defects and severe pulmonary arterial hypertension. Int J Cardiol 147(3):433\u2013437","journal-title":"Int J Cardiol"},{"issue":"5","key":"1914_CR26","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1378\/chest.129.5.1313","volume":"129","author":"A Fijalkowska","year":"2006","unstructured":"Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P et al (2006) Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129(5):1313\u20131321","journal-title":"Chest"},{"issue":"4","key":"1914_CR27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.amjcard.2006.02.061","volume":"98","author":"AK Andreassen","year":"2006","unstructured":"Andreassen AK, Wergeland R, Simonsen S, Geiran O, Guevara C, Ueland T (2006) N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 98(4):525\u2013529","journal-title":"Am J Cardiol"},{"issue":"11","key":"1914_CR28","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.amjcard.2011.07.025","volume":"108","author":"G-J Mauritz","year":"2011","unstructured":"Mauritz G-J, Rizopoulos D, Groepenhoff H, Tiede H, Felix J, Eilers P et al (2011) Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol 108(11):1645\u20131650","journal-title":"Am J Cardiol"},{"key":"1914_CR29","author":"D Henrohn","year":"2015","unstructured":"Henrohn D, Sandqvist A, Eger\u00f6d H, Hedeland M, Wernroth L, Bondesson U et al (2015) Changes in plasma levels of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine after a single dose of vardenafil in patients with pulmonary hypertension. Vascul Pharmacol. doi: 10.1016\/j.vph.2015.04.010","journal-title":"Vascul Pharmacol"},{"issue":"7","key":"1914_CR30","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1161\/01.ATV.0000168414.06853.f0","volume":"25","author":"JT Kielstein","year":"2005","unstructured":"Kielstein JT, Bode-B\u00f6ger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D et al (2005) Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler, Thromb, Vasc Biol 25(7):1414\u20131418","journal-title":"Arterioscler, Thromb, Vasc Biol"},{"issue":"11","key":"1914_CR31","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/rheumatology\/ken346","volume":"47","author":"T Dimitroulas","year":"2008","unstructured":"Dimitroulas T, Giannakoulas G, Sfetsios T, Karvounis H, Dimitroula H, Koliakos G et al (2008) Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. Rheumatol Oxf Engl 47(11):1682\u20131685","journal-title":"Rheumatol Oxf Engl"},{"issue":"11","key":"1914_CR32","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1164\/rccm.200702-278OC","volume":"176","author":"N Skoro-Sajer","year":"2007","unstructured":"Skoro-Sajer N, Mittermayer F, Panzenboeck A, Bonderman D, Sadushi R, Hitsch R et al (2007) Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 176(11):1154\u20131160","journal-title":"Am J Respir Crit Care Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1914-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-015-1914-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1914-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T21:30:15Z","timestamp":1567027815000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-015-1914-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,5]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["1914"],"URL":"https:\/\/doi.org\/10.1007\/s00228-015-1914-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,5]]}}}